There are growing data to suggest that tissue hypoxia represents a critical force that drives adult vasculogenesis. Vascular endothelial growth factor (VEGF) expression is dramatically up-regulated by hypoxia and results in enhanced neovascularization. Although the role of VEGF in angiogenesis has been well characterized, its role in adult vasculogenesis remains poorly understood. We used two distinct murine bone marrow transplantation (BMT) models to demonstrate that increased VEGF levels at the site of tumor growth promoted vasculogenesis in vivo. This effect of VEGF was downstream of its effect to enhance either mobilization or survival of circulating endothelial progenitor cells (EPCs). Both VEGFR1 (flt1) and VEGFR2 (flk1) are expressed on culture expanded human EPCs. Previous studies suggest that the effect of VEGF on endothelial cell migration is primarily mediated via VEGFR2; however, VEGF-induced EPC migration in vitro was mediated by both receptors, suggesting that VEGF-VEGFR1 interactions in EPCs are distinct from differentiated endothelial cells. We used specific blocking antibodies to these receptors to demonstrate that VEGFR1 plays an important role in human EPC recruitment to tumors. These findings were further supported by our finding that tumor-associated placental growth factor (PlGF), a VEGFR1-specific agonist, increased tumor vasculogenesis in a murine BMT model. We further showed that both VEGF receptors were necessary for the formation of functional vessels derived from exogenously administered human ex vivo expanded EPCs. Our data suggest local VEGF and/or PlGF expression promote vasculogenesis; VEGF plays a role in EPC recruitment and subsequent formation of functional vessels.-Li, B., Sharpe, E. E., Maupin, A., Teleron, A. A., Pyle, A., Carmeliet, P., Young, P. P. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J. 20, E664 -E676 (2006) 
The role of vasculogenesis during postnatal neovascularization in both pathological and physiological conditions is under intense study (1) (2) (3) . Multiple, recent studies have demonstrated that ex vivo isolated, cultureexpanded endothelial progenitor cells (CE-EPCs) from human peripheral blood (hPB) are preferentially recruited to sites of ischemia and tumor formation, incorporate into functional vasculature, and promote vascularization (4 -8) . However, the mechanisms by which circulating EPCs are recruited to sites of neovascularization remain incompletely understood (2, 3, 9) .
Recently, it has been proposed that postnatal vasculogenesis is driven primarily by local tissue ischemia, and this is likely to involve the local release of soluble factors that promote EPC recruitment (10 -12) . The chemokine, stromal cell-derived factor-1 (SDF-1), has been well characterized as a mediator of hematopoietic stem cell recruitment and homing (13) . More recently, it has been shown to be involved in hypoxia-mediated recruitment of CE-EPCs in mouse models of tissue ischemia (14 -18) . Other cytokines are also known to be up-regulated by hypoxia (19) . Perhaps the most widely studied of these is the endothelial cell (EC) mitogen, vascular endothelial growth factor (VEGF; also known as VEGF-A; refs. 20, 21) . The role of VEGF in angiogenesis is well established by both in vitro and in vivo studies (21) . VEGF has also been shown to be important in recruiting myeloid cells to tumor site (22) . However, its role in postnatal vasculogenesis is not well understood (1, 3, 21, 23) . Thus far, multiple groups have shown that recombinant VEGF promotes mobilization of immature hematopoietic progenitors into peripheral circulation as well as the numbers of CEEPCs/ml of peripheral blood (PB) in mice (24, 25) . Consistent with that observation, blocking VEGFR2 signaling resulted in poor mobilization of EPCs (26) . The presence of tissue ischemia, which resulted in increased circulating VEGF levels, also increased circu-lating progenitors and CE-EPCs in mice and humans (11, 27, 28) .
In our previous work, we showed that coadministration of recombinant VEGF with donor bone marrow (BM) cells to neonatal mice promoted engraftment of donor-derived ECs into recipient liver and heart, suggesting that the effect of VEGF may be downstream of EPC mobilization (29) . This finding was supported by another study in which VEGF 164 gene transfer augmented proliferative activity, adhesion, and incorporation of CE-EPCs to EC monolayers in vitro and in vivo engraftment to ischemic limbs (30) .
VEGF regulates blood vessel growth primarily by interacting with two cell surface tyrosine kinase receptors, VEGF receptor-1 (VEGFR1 or flt1) and VEGF receptor-2 (VEGFR2 or flk1; ref 21 ) and with membrane protein neuropilin-1, which does not contain a tyrosine kinase domain (31) . VEGFR1 and VEGFR2 have distinct functions during embryonic vasculogenesis (32, 33) . Whereas absence of VEGFR2 results in complete absence of both ECs and hematopoietic cells (32) , ablation of VEGFR1 results in abundant ECs but failure to form functional vessels (33) . The role of these receptors in postnatal vasculogenesis has not been well studied. There has been growing interest in placenta growth factor (PlGF), a member of the VEGF family that binds specifically to VEGFR1, and its role in tumor vascularity. PlGF has been found to promote tumorigenesis in mice, and very recent studies report PlGF overexpression in human cancers (34 -37) . In this study, we provide data to support the hypothesis that VEGF promotes tumor vasculogenesis by promoting EPC chemotaxis, recruitment (through VEGFR1), and vessel formation. We also investigate the role of PlGF in tumor vasculogenesis.
MATERIALS AND METHODS

Mice and cell lines
The NOD/LtSz-scid (NOD/SCID) mouse with a deficiency in ␤-glucuronidase (GUSB) activity (NOD/SCID/GUSB Ϫ/Ϫ ) was recently generated (38) and bred in a colony maintained by P. P. Young at Vanderbilt University School of Medicine. Offspring homozygous for the GUSB mutation (NOD/SCID/ ␤-glucuronidase Ϫ/Ϫ ) were identified by a specific polymerase chain reaction (PCR) assay (29, 38) . The GUSB Ϫ/Ϫ tumor line arose spontaneously in a homozygous NOD/SCID mouse and was passaged in culture, and cells from passage 6 -20 were used for all experiments. Tumor cell proliferation in vitro was not affected by rVEGF (10 uM) . To measure tumor vasculogenesis, GUSB Ϫ/Ϫ mice were transplanted with BM from syngeneic GUSB ϩ/ϩ donors resulting in GUSB/BMT. After hematopoietic engraftment, mice were implanted with tumors that were analyzed by quantitative enzyme (39) , flow cytometric (29) , and immunofluorescent GUSB assays (29) to determine BM engraftment and EPC recruitment.
For CE-EPC recruitment studies, after tumor growth Ϸ0.5 cm 3 (10 days after 1ϫ10 6 cells were implanted in untransplanted GUSB Ϫ/Ϫ mice), 5 ϫ 10 5 hPB-derived CE-EPCs were preincubated for 1 h at 4°C with 8 g of neutralizing antibody to either VEGFR1 (clone 6.12, IgG1, ImClone Systems) or VEGR2 (clone 89106, IgG1, R&D Systems) or control mouse IgG without serum. Cells were washed in PBS after incubation and subsequently injected intravenously by tail vein into tumor-bearing recipients. Mice were killed 12 h later and tumor tissue, and lung and skeletal muscles were removed for quantitative GUSB analysis. Six mice were used for each condition (nϭ18) over three independent experiments. To study in situ vessel formation, hPB-derived CE-EPCs were preincubated with anti-VEGFR antibodies (as noted above) or control mouse IgG, washed, and then admixed with tumor cells before subcutaneous implantation in untransplanted GUSB Ϫ/Ϫ mice. After 8 days, the mice were killed and the tumor was removed for histochemical and immunofluorescent analysis to identify GUSB-positive, human vessels using human specific anti-von Willebrand factor (vWF; VW1-2, Takara). Each animal received all three conditions, and three animals were used for this experiment.
Flk-1/LacZ mice in C57Bl/6 background (Jackson Laboratory) represent mice heterozygous for the VEGFR2 null mutation in which the target gene was replaced with a promoterless lacZ gene from Escherichia coli. In the heterozygous mouse (flk/lacZ), expression of lacZ is subject to regulation by an EC-specific promoter (32) . Wild-type littermates transplanted with BM from flk/lacZ transgenic donors, generating flk/lacZ/BMTs. BMT mice were injected subcutaneous in one flank with 1 ϫ 10 6 B16F10 mouse melanoma tumor cells [American Type Culture Collection (ATCC)] that had been stably transfected with VEGF cDNA (nϭ7) or mouse PlGF2 cDNA (nϭ6) or with vector control in the contralateral flank (34) . Two to four clones of each type were combined before injection. Animals were killed 14 days later, and tumors were resected and measured as described above. Donor BM-derived vessels (lacZ-positive) were distinguished by histochemistry, immunofluorescence, and quantitative ␤-galactosidase (␤-gal) assay.
For BMT, unfractionated BM from syngeneic donor mice was obtained as described (29) . We injected 5 ϫ 10 6 nucleated cells through the lateral tail vein from same sex donors into recipients that had been preconditioned with either 300 (NOD/SCID) or 800 (C57Bl/6) rads of ␥-radiation from a 137 Cs source. This concentration of radiation resulted in Ͼ95% engraftment in all animals studied (data not shown). Studies post-BMT were performed 2 months after transplant. All protocols were approved by the Vanderbilt Institutional Animal Care and Use Committee.
CE-EPC culture
Human peripheral blood (hPB) leukocytes were isolated from human blood donor leukocyte reduction filters (LeukotrapRC, Pall Corporation) that were obtained from the American Red Cross (Nashville, TN) as described previously (40) ; three to four filters were pooled per prep to reduce donor variability. Mononuclear cells (MNCs) were isolated from blood leukocytes by density centrifugation and were directly plated at 1 ϫ 10 8 cells/cm 2 on 100 mM culture dishes or on 22 mm 2 glass coverslips (placed in 6-well plates) coated with human fibronectin (Sigma) diluted 1:50 in HBSS and maintained in EBM-2 (Clonetics) with supplements as described previously (40, 41) . CE-EPCs were used after 7 days by detaching with PBS and 1 mM EDTA.
Cell lines and generation of stable transfectants
Human umbilical vein endothelial cells (HUVECs; ATCC) and human microvascular endothelial cell (HMEC) (CDC, Atlanta) were maintained in EBM-2 with supplements. B16F10 murine melanoma cells (ATCC) were grown in Dulbecco's modified Eagle's medium media with 10% FCS, at 37°C with 5% CO 2 . Stable transfections with pcDNA3 plasmid encoding VEGF 164 or PIGF-2 cDNA driven by the cytomeglovirus promoter were carried out with Lipofectamine 2000 (Invitrogen Life Technologies). After selection for 14 days with 1500 g/ml G418 (Sigma), individual colonies were picked into 24-well plates cultured with medium containing 500 g/ml G418. Mouse VEGF and PlGF-2 secreted into culture medium were measured as described by ELISA Quantikine kits (R&D Systems).
Quantitative enzyme biochemistry
Tissues were homogenized (150 mM NaCl, 10 mM Tris, pH7.5, 0.2% Triton X-100, and 1 mM DTT), and samples were centrifuged at 14,000 g for 15 min, 4°C. To quantify ␤-gal activity, 50 l of homogenized tumor tissue from flk/lacZ/BMT was tested in triplicate following the manufacturer protocol in the All-in-One ␤-gal assay reagent (Pierce), PBS alone, as well as samples obtained from wild-type mice, was used as negative control. Tumors from flk/lacZ mice served as positive control.
For GUSB-specific biochemical assay, a portion of tissue homogenates were incubated at 37°C for 1 h in 100 l 5 mM 4-MU-␤-d-glucuronide substrate (Sigma). Reactions were stopped with 0.1 M sodium carbonate and then assayed fluorometrically as described previously (42) . Specific activity (1 Uϭ1 nmol substrate cleaved/h/mg protein) was calculated for lung and liver; total tumor GUSB activity was calculated by multiplying specific activity by total tumor mass. The protein concentrations were measured by using the Coomassie dye binding assay (Pierce).
Migration assay
CE-EPCs, HUVECs, or HMECs (8ϫ10 5 for all) were isolated by EDTA treatment and incubated in the presence of anti-VEGFR1 (clone 6.12, Imclone Systems), -VEGFR2 (Clone 89106, R&D Systems), or -CXCR4 (clone 44716, R&D Systems) or control mouse IgG for 1 h on ice and then added to the upper chamber. Migration was assessed after 5 h using a modified Boyden chamber assay as described previously (43) . Migrating cells adhering to the undersurface of the filters were fixed and stained with crystal violet and counted. Results are indicative of four independent experiments performed in duplicate. Quantitative (q)RT-PCR to examine VEGF receptors were performed as described previously (44) . Primer sequences are available on request.
Histochemistry, immunofluorescence, immunohistochemistry, and morphometry
Tissues were collected and processed as described previously (29) . For immunofluorescence, sections were fixed for 20 min at 4°C in 100% acetone and then incubated with MOM block [5% (wt/wt) papain/2 uM EDTA, pH 7.4, and 20 mM l-cysteine] at dilution of 1:20, a PBS-blocking buffer (0.01 g/ml BSA/2 g powdered milk/ml, and 3 l/ml Triton X-100) and 10% v/v goat serum for 1-2 h as described previously (29) . Fluorescent staining of adherent cells on glass cover slips was conducted after 7 days in culture (40) . The images were visualized using a Ziess Axioplan 2 microscope equipped with a 20ϫ/0.75 objective lens (Carl Ziess MicroImaging). Images were photographed with a CoolSNAP Hq CCD camera (Photometrics) and acquired with Metamorph v5.0 software (Universal Imaging Corporation). For GUSB-specific histochemical assay, samples were frozen in OCT embedding medium (Sakura, Torrance, CA) for histochemical analysis; 10 m sections were stained for active GUSB as described previously by using naphthol-AS-BI-␤-dglucuronide (Sigma) as a substrate and then counterstained with methyl green (42) . For ␤-gal staining, frozen sections were prepared and stained as described previously (45) . In parallel, paraffin embedded, formalin fixed tissue slides were also stained with a polyclonal antibody to ␤-gal (1:1000, Novus) and analyzed using histochemistry (46) . Histochemistry for GUSB was performed as described previously (46) . To determine whether CE-EPCs formed functional vessels, animals were injected intravenously with biotinylated BS-1 lectin (200 l of 500 g/ml; Vector Labs) 30 min before death. Tumors were resected, embedded in OCT, and processed as described before staining (29) . Coimmunofluorescent staining was performed with human-specific vWF and lectin was detected by rhodamine streptavidin.
Flow cytometry
Tumor tissues from GUSB/BMT were finely minced, washed to remove tumor-associated leukocytes, and treated with collagenase type IV (1 mg/ml, Worthington) for 30 min. Large debris was allowed to settle, and the suspension was red cell lysed and analyzed as described previously by using a fluorogenic GUSB substrate (Molecular Probes; ref 29) and VE-cadherin/PE (BV9, Cell Sciences). Tumor suspensions obtained from GUSB-negative and GUSB-positive animals were used as negative and positive controls, respectively, and used to set the GUSB gates. Isotype control antibodies were used as control for the VE-cadherin Ab. Nonviable cells, identified by 7-aminoactinomycin D (7-AAD; Molecular Probes) staining, were excluded. Quantitative analyses were performed on a FACScan flow cytometer and subsequently analyzed using Cellquest software (Becton-Dickinson).
Antibodies used for cell/tissue staining
Active caspase 3 (Promega), polyclonal hVEGFR2 (R&D Systems), hVEGFR1 (89106, R&D Systems), polyclonal hTie-1 (Santa Cruz), polyclonal Tie-2 (Santa Cruz), hVE-Cadherin (BV9, Cell Sciences), human-specific vWF (VW1-2, Takara), vWF (Dako), and polyclonal goat anti-human GUSB (provided by M. S. Sands). Appropriate secondary antibodies were purchased and used from Jackson ImmunoResearch and Molecular Probes.
Statistical analysis
Two-tailed paired Student's t tests were performed to compare different data sets in which appropriate. All data are mean Ϯ se; P Ͻ 0.05 denotes statistical significance.
RESULTS
Recombinant VEGF admixed with tumor cells increased BM-derived ECs in tumors
We used two different mouse models of tumor growth to quantify the effect of VEGF on vasculogenesis. The first model used the GUSB-deficient mouse engrafted with GUSB-positive (wild-type) BM, resulting in GUSB/ BMT (Fig. 1E ). This BMT model has been previously used to study the in vivo role of EPCs (29) . GUSB is a lysosomal enzyme that is expressed in virtually all cell types, including BM-derived cells (47) . On transplanta-tion into a GUSB-deficient host, cells from normal mouse or human donors can be identified by virtue of their GUSB expression with several sensitive biochemical and histochemical assays (42) . A spontaneously occurring tumor was isolated from a GUSB-deficient mouse. Histological analysis of H&E stained sections from formalin-fixed, paraffin-embedded tumor tissue suggested that this was a malignant high-grade sarcoma ( Fig. 1A-B) . The tumor was negative for lysozyme sarcoplasmic actin, CD31, keratin, LCA, factor 13, vimentin, NE filament, ubiquitin, vWF, desmin, and HHF 35. The tumor was positive for CD117 (ckit), actin, and reticulin (Young and Vogler, data not shown). These findings excluded the diagnosis of angiosarcoma. Absence of GUSB enzyme activity was confirmed by two methods. First PCR analysis was performed on the tumor to demonstrate GUSB-specific mutation (Fig. 1D) . Second, histochemical stain for GUSB performed on a frozen section of the primary tumor tissue demonstrated the absence of GUSB enzyme activity (Fig 1C) . To determine tumor growth kinetics, 8-to 10-wk-old NOD/SCID mice both homozygous or wild type for the GUSB mutation were injected subcutaneously with 5 ϫ 10 5 GUSB Ϫ/Ϫ tumor cells admixed with VEGF (16 ng/ml) and heparin in one flank and without VEGF in the contralateral flank. Mice were killed, and tumor volume was determined using the formula 0.52 ϫ width 2 ϫ length ( Fig. 1F ; ref. 43 ). Because there were no statistical differences in tumor growth among animals homozygous for GUSB mutation from wild type, the data were combined. Faster growth in VEGF admixed tumor was evident by day 5 (Fig. 1F ). We confirmed no direct effect of VEGF on tumor proliferation (data not shown). To determine whether BM-derived cells were contributing to tumor vasculature, we examined tumors obtained from GUSB/BMT after confirming Ͼ90% donor engraftment ( Fig. 1E depicts the experimental design; ref 29) . Each transplanted recipient received subcutaneous implantation of 2 ϫ 10 6 GUSB Ϫ/Ϫ tumor cells with and without admixed VEGF in opposing flanks. The mice were killed either 5 (nϭ15) or 25 (nϭ6) days later, and tumors were analyzed for GUSB-positive (BM-derived) vessels. Donor-derived, GUSB-positive vascular structures that also costained with BS1 lectin (to mark blood vessels) were evident in tumors from both time points ( Fig. 2A shows only day 25 data) and clustered around tumor periphery. To determine whether VEGF affected the numbers of BM-derived cells within the tumor, we quantified GUSB-enzyme activity of tumor homogenates obtained at both time points. Tumor tissue admixed with VEGF that were obtained 5 days after implantation contained a fourfold greater GUSB specific activity than contralateral tumors without VEGF (Fig. 2B ). No statistical difference was evident between the VEGF vs. control samples for day 25 samples (Fig.  2B ). Since GUSB enzyme activity was present in all BM-derived cells and did not selectively quantify BMderived ECs, we used flow cytometric analysis of collagenase-treated tumor suspensions to quantify the numbers of GUSB-positive (BM-derived) cells that coexpressed VE-cadherin, a marker specific for ECs (Fig.  2C-D shows the control samples used to establish the gates and representative analysis of tumor suspensions obtained after day 5 of implantation). VEGF-containing tumors contained significantly greater percentage of BM-derived ECs (GUSB/VE-cadherin dual positive), 30.8 Ϯ 8.2 vs. 10 Ϯ 4.8%, P Ͻ 0.05, but only in tumors obtained 5 days after implantation (Fig. 2E-G ). This effect of VEGF was not statistically different from control in tumors obtained 25 days after implantation. The lack of effect of VEGF at day 25 may be due to the short bioavailability of the admixed VEGF. The analysis of tumor homogenates after 5 days of implantation supported our hypothesis that locally increased VEGF levels promoted tumor vasculogenesis. 
Flk/lacZ/BMT model showed that increased local VEGF-promoted tumor vasculogenesis
We confirmed these findings with a second, independent mouse BMT model using transgenic mice that constitutively expressed ␤-gal (lacZ) transcriptionally regulated by an EC-specific promoter, VEGFR2 (flk1; ref 32, 48) . They will be noted as flk/lacZ/BMT. The absence of a single VEGFR-2 allele on the EPCs may result in underestimation of vasculogenesis in this model by reducing donor-derived EPC recruitment or assembly into vessels. The use of this model, however, enabled clear distinction of vasculogenesis from angiogenesis, because the expression of lacZ in tissues was restricted to BM-derived cells of the EC lineage (32, 48) . B16F10 melanoma clones stably expressing murine VEGF 164 cDNA or stably transfected with control plasmid expressed 27.4 Ϯ 6.4 vs. 12.7 Ϯ 6.3 pg VEGF/g total protein, respectively (Pϭ0.01). Clones overexpressing VEGF were also compared with control in a proliferation assay to exclude direct effects of VEGF on tumor proliferation (data not shown). VEGF-overexpressing clones were combined and implanted subcutaneously into the left flank of flk/lacZ/BMT mice. The right flank was implanted with equal numbers of B16F10 cells that had been stably transfected with control plasmid. Animals were sacrificed, and tumor growth and vasculogenesis were analyzed after 14 days (schematic in Fig. 3A) . As expected, the tumor volume generated by VEGF-overexpressing melanoma cells was significantly larger, Ͼ16-fold (Fig. 3B) , than the contralateral nonvascular VEGF overexpressing tumor in each mouse (nϭ7), although there was wide variation in the size of tumors generated from mouse to mouse. Immunohistochemistry using anti-␤-gal antibody (Fig.  3C ) of tumors from flk/lacZ (untransplanted) animals confirmed ubiquitous lacZ-positive vascular structures, whereas tumors from wild-type mice not expressing the lacZ transgene were devoid of positive staining (shown in Fig. 3A inset as negative control) . Immunohistochemistry was also performed on tumors obtained from flk/lacZ/BMT to identify donor-derived (lacZ ϩ /vasculogenic) vessels. Few (Ͻ5%) lacZ-positive vessels were evident in control tumors, and almost all were located in the tumor periphery (Fig. 3D) . A greater number of lacZ-positive cells, again located primarily in the periphery, were identified in most sections of tumors obtained from VEGF-overexpressing tumors (Fig. 3E-F) . To quantify tumor vasculogenesis, we measured ␤-gal enzyme activity in tumor homogenates obtained from half of each resected tumor mass. This avoided sampling error caused by quantifying immunoreactive areas on multiple histological sections. The average ␤-gal activity in control tumors vs. VEGF-overexpressing tumors was 0.65 Ϯ 0.33 and 1.6 Ϯ 0.77 optical density (OD)/mg total protein P Ͻ 0.05, respectively. The average ratio of ␤-gal activity between VEGF and control tumor pairs isolated from each mouse is shown (Fig. 3G) . This difference was supported by our qualitative analysis (data not shown). Hence, tumor cells that over-expressed VEGF exhibited an Ϸ2.5-fold increase in vasculogenesis.
VEGFR1 mediates EPC recruitment to site of tumorigenesis
Both in vivo models suggested that local VEGF expression increased vasculogenesis. Several studies have shown that CE-EPCs, generated after ex vivo expansion and differentiation of hPBMNCs, home to the site of neovascularization and incorporate into new vessels and promote vascularization (4, 5) . Phenotypic characterization of hPB-derived CE-EPCs confirmed the expression of various EC marker proteins such as VEGFR1, VEGFR2, VE-cadherin, tie-1, tie-2, vWF, and UEA-1 lectin and uptake of DiI-acLDL (data not shown; ref 40) . The role of VEGFRs in EPC recruitment in vivo was investigated by preincubation of CE-EPCs with receptor-specific antibodies that blocked both ligand binding and activation (49) . After tumors were evident, mice were injected intravenously with 5 ϫ 10 5 CE-EPCs preincubated with either anti-VEGFR1-, -VEGFR2-blocking antibodies or control IgG (Fig. 4A depicts  experimental design) . Since homing of stem and progenitor cells is believed to occur within 6 -12 h (50, 51), the mice were killed 12 h after administration. The tumors were homogenized and assayed for GUSB enzyme activity as a quantitative marker for administered CE-EPCs. To control for experimental variation in total number of EPCs administered, the total tumor GUSB activity from each animal was normalized to lung GUSB specific activity before calculating fold change between experimental groups. GUSB specific activity (1 Experimental schematic used to study role of VEGFR1 vs. VEGFR2 in CE-EPC recruitment to tumor. Briefly, after tumor growth, GUSB Ϫ/Ϫ mice were injected with GUSB ϩ/ϩ EPCs preincubated with either VEGFR1-or VEGFR2-blocking antibodies. GUSB activity at tumor site was measured after 12 h as a surrogate measure of EPC recruitment. B) Fold change in total GUSB enzyme activity in tumor homogenates as a quantitative measurement for CE-EPC homing to tumor site after preincubation with control IgG, or antibodies to VEGFR1 or VEGFR2. C) Schematic shows flk/lacZ/BMT model used to study role of PlGF (a specific ligand for VEGFR1) in tumor vasculogenesis. Tumor cells stably transfected with vector were implanted subcutaneously in right flank; left flank received tumor cells stably transfected with vector encoding PlGF. Tumors were analyzed after day 14 postimplantation. D) Average of the fold change in tumor volumes generated by PlGF overexpressing B16F10 tumor cells vs. control obtained from the same mouse 2 wk after implantation (nϭ6). E) Bl6F10 PlGF -derived tumors obtained from flk/lacZ/BMT demonstrated several red blood cell containing, LacZ-positive vessels (arrow). F) Fold change in ␤-gal enzyme activity, as a marker for donor (BM-derived) vessels, was measured in PlGF-overexpressing and control B16F10 tumor homogenates residing within the same mouse to quantify the effect of PlGF on vasculogenesis.
Uϭnmol/mg protein/h) in lung (as an example of normal tissue) was very low and similar between treated and control animals, 140 Ϯ 20 vs. 110 Ϯ 29 U, respectively. By contrast, GUSB specific activity in tumor tissue was Ϸ10-fold (1320Ϯ80 U) higher than that in lung in control animals (nϭ3). Preincubation with VEGFR1 antibody resulted in a 5-fold decrease in total GUSB activity in tumors as compared with tumors from mice receiving EPCs preincubated with control IgG (Fig. 4B;  Pϭ0.001) . Preincubation of EPCs with anti-VEGFR2 antibody also diminished EPC homing to tumors, as determined by measuring fold change in GUSB activity, but this difference was not statistically significant ( Fig.  4B; Pϭ0.13 ).
Tumor-associated PlGF increases tumor vasculogenesis
Our unexpected finding that VEGFR1 affects CE-EPC recruitment to tumor site led us to hypothesize that the VEGFR1-specific agonist PlGF also promotes vasculogenesis. To test this hypothesis, we generated stable transfectants of B16F10 melanoma cells overexpressing PlGF cDNA or control plasmid. Pooled clones expressed a 2.3-fold higher PlGF2 protein than pooled control transfectants (1112 vs. 492 pg/ml medium PϽ0.001, data not shown). A cell proliferation assay was used to exclude direct effects of PlGF on tumor proliferation (data not shown). PlGF-overexpressing clones were implanted subcutaneously into the left flank of flk/lacZ/BMT mice and equal numbers of control B16F10 cells into the right flank (Fig. 4C shows schematic). Tumors were analyzed after 14 days. Local overexpression of PlGF enhanced tumor size over control by Ϸ4-fold (nϭ6; Fig. 4D ), consistent with published reports (34) . Immunohistochemistry using anti-␤-gal antibody of tumors obtained from flk/lacZ/BMT to identify donor-derived (lacZ ϩ /vasculogenic) vessels of control tumors showed very few positive cells (representative image in Fig. 3D) . A greater number of lacZ-positive cells occurring in clusters were identified in several sections of tumors obtained from PlGFoverexpressing tumors (Fig. 4E) . To quantify tumor vasculogenesis between PlGF and control tumors, we measured ␤-gal enzyme activity in tumor homogenates obtained from half of both control-and PlGF-expressing tumors. The average ␤-gal activity in control tumors vs. PlGF-overexpressing tumors was 0.33 Ϯ 0.14 and 0.64 Ϯ 0.09 OD/mg total protein, P Ͻ 0.05, respectively, Ϸ2-fold difference (Fig. 4F) . These data suggest that tumor-derived PlGF also promotes formation of BM-derived blood vessels.
VEGFR-blocking antibodies prevent CE-EPC-mediated vessel formation in tumors
VEGFR2 is known to be critical for EC survival and hence likely to be important for CE-EPCs (21) . To distinguish CE-EPC survival and vessel formation from recruitment effects of receptor-blocking antibodies, we preincubated 5 ϫ 10 5 CE-EPCs in the presence of anti-VEGFR2 or -VEGFR1 antibodies or IgG control for 60 min before admixing them with 2 ϫ 10 6 tumor cells and implanting them subcutaneously. Each mouse was implanted with all three conditions, thereby generating 3 foci of solid tumors. Tumors were removed after 8 days for analysis of functional vessel formation by GUSB-positive CE-EPCs. Control tumors contained numerous GUSB-positive cells, many that had assembled into vascular-like structures (Fig. 5A) . Abundant GUSBpositive cells were also evident in tumors to which CE-EPCs preincubated with VEGFR1 antibodies had been added (Fig. 5B) ; however, no cord-like structures were evident. Unlike VEGFR1-blocking antibodies, the presence of VEGFR2-blocking antibodies significantly diminished the numbers of intact CE-EPCs in tumors as determined by counting intact numbers of GUSBpositive cells in 5 representative fields each from three different tumors (Fig. 5C, J) . VEGFR2 has been shown to be important for EC survival (21); hence, we examined the section for evidence of increased CE-EPC apoptosis using an antibody recognizing active caspase 3. Few intact, isolated GUSB-positive cells were detected in tumors containing CE-EPCs pretreated with VEGFR2 (Fig. 5G) ; several of the immunoreactive cells costained for active caspase 3 (Fig. 5H, merge in inset) . No caspase-3/GUSB ϩ dual positive CE-EPCs were identified in samples preincubated with VEGFR1 blocking antibodies (Fig. 5I) . CE-EPC-derived functional vessels (incubated with control IgG) were identified in tumors by colocalizing cells positive for human-specific antivWF antibody with BS1-lectin positive structures, which marked functional tumor vessels (Fig. 5D-F) . However, preincubation of the CE-EPCs with either anti-VEGFR1 or -R2 disrupted vessel formation, as no vWF-positive vessels were detected within tumors (Fig 5B-C, insets) . Thus, either VEGFR1 or VEGFR2 blocking antibodies prevented CE-EPC assembly into vessels within the tumor mass.
VEGF/VEGFR1 interactions play a unique role in VEGF-mediated CE-EPC migration in vitro
Published studies suggest that VEGF-induced EC migration, survival, and proliferation are mediated primarily by VEGFR2 (21, 52) . Hence, we were surprised to identify VEGFR1 as an important mediator of CE-EPC recruitment to the tumor site. Using a modified Boyden chamber migration assay, we examined the role of VEGFR1 and VEGFR2 in mediating in vitro CE-EPC chemotaxis in response to VEGF as compared withECs (e.g., HUVECs and HMECs; Fig. 6A-D) . CE-EPCs migrated in a dose-dependent manner to both VEGF and the VEGFR1-specific agonist, PlGF (Fig. 6B) . To examine receptor specificity, CE-EPCs were preincubated in receptor-blocking anti-VEGFR1 or -VEGFR2 for 60 min before migration assay (Fig. 6C) . Cell viability of nonmigrated cells at the end of the assay was Ͼ90% (data not shown). Migration of CE-EPCs was equally responsive to PlGF, a VEGFR1-specific agonist (53), as VEGF (Fig. 6B-C) . Concentration of inhibition by VEGFR1 blocking antibody was commensurate with blocking anti-VEGFR2. By contrast, in vitro migration in response to VEGF of HMECs (Fig. 6D) and HUVECs (data not shown) was mediated primarily by VEGFR2, consistent with published studies (21, 52) . By (q)RT-PCR, we found that relative VEGFR2 transcript levels in cultured EPCs obtained from independent preparations were 75-fold (Pϭ0.004) lower than ECs (i.e., HMECs), whereas VEGFR1 transcript levels were consistently Ϸ3-fold higher (Pϭ0.008) than in ECs, and neuropilin transcript levels were not statistically different between ECs and EPCs. Hence, unlike ECs, CE-EPCs express relatively higher levels of VEGFR1 transcripts, and their migration in vitro was mediated by both receptors.
No crosstalk between SDF-1-and VEGF-mediated migratory signals
Recently, it has been shown that the rise in plasma SDF-1 after insult is correlated with an increase in numbers of CE-EPCs that can be obtained from culturing human periferal blood MNCs (14 -18) . Tissue SDF-1 is also increased during ischemia and has been shown to recruit CE-EPCs. We were interested in determining if there was crosstalk between the SDF-1 and VEGF pathway in mediating CE-EPC migration in vitro.
Migration of CE-EPCs to rVEGF (17 nM) was similar to migration in response to 13 nM SDF-1 in a modified Boyden chamber assay (Fig. 6E) . The combination of VEGF and SDF-1 resulted in an additive increase in CE-EPC migration. Preincubation of CE-EPCs with neutralizing antibodies against CXCR4 did not diminish VEGF-induced migration but did abolish migration in response to SDF-1. Conversely, neutralizing antibody against VEGFR1 and VEGFR2 abolished migration in response to VEGF but failed to affect migration in response to SDF-1 (Fig. 6E) . These data suggest that VEGF and SDF-1 mediated CE-EPC migration is mediated by independent mechanistic pathways.
DISCUSSION
The proangiogenic functions of VEGF have been extensively studied (21, 54) . Less well understood is its precise role in vasculogenesis (32, 33, (55) (56) (57) (58) (59) . There are emerging data that VEGF is also important in postnatal vasculogenesis, specifically in EPC mobilization into the circulation (18, 24 -26, 30) . Coadministration with BM resulted in increased vasculogenesis in a neonatal model (29) . Finally, VEGF gene transfer into CE-EPCs promoted survival and adhesion in vitro and subsequently resulted in greater engraftment in vivo (24, 30) . In this study, we further defined how VEGF may promote vasculogenesis. We show that VEGF overabundance at the site of tumor growth results in increased vasculogenesis using two different murine BMT models. In the first model, rVEGF admixed with tumor cells elicited 3-fold greater numbers of donor BM-derived ECs that was evident at 5 days of growth, but not after 25 days, a likely result of admixing recombinant VEGF (with limited half-life) at time of implantation. The finding that the enhanced vasculogenesis observed at early time points (when VEGF was available) did not persist at the later time point supports the notion that vasculogenic vessels regress over time. This is also supported by our observation that majority of the donor-derived vessels were located selectively in the periphery of the tumor. Aspects such as stability, remodeling, or expansion of postnatal vessels derived from vasculogenesis have not been well studied.
The second BMT model used tumor cells that were stably transfected with VEGF. In control tumors, the number of donor-derived, lacZ positive cells was rare in most histological fields. At 14 days of tumor growth in this model, vasculogenesis was 2.5-fold greater in VEGFoverexpressing tumors by a quantitative measurement of lacZ (expressed in only BM-derived vessels). Since the VEGF and control sites were within the same animal in both models, the effect of VEGF was local and not secondary to EPC mobilization or direct effects of VEGF on survival and adhesion of the circulating vascular stem cell population. Our data support a role of VEGF downstream of EPC mobilization or general effects on the circulating EPC population.
We further show that the VEGFR1 agonist PlGF, expressed by tumor cells, also led to an almost twofold increase in vasculogenesis over control. Interestingly, PlGF has been shown to enhance tumor growth and vascularity in mice (34) , and more recently, its overexpression has been associated with worse prognosis in human tumors (35) (36) (37) . To our knowledge, the role of PlGF in vasculogenesis has not been reported. Together, the VEGF and PlGF data support the hypothesis that the local microenvironment (i.e., local VEGF and/or PlGF levels) plays an important role in vasculogenesis. The present findings help to address the controversy resulting from the wide variation in the degree of tumor vasculogenesis observed in different model systems (22, 60 -62) . Some studies have demonstrated substantial contribution of EPCs to tumor endothelium. Absence of EPC-derived vessels in other studies may be the result of different models systems (e.g., use of different reporter constructs, such as SCL or different tumor types) or in method of tissue sampling. For example, we found substantially greater levels of vasculogenesis in the GUSB Ϫ/Ϫ tumors than in the B16F10-derived tumors. Although we did not rigorously quantify the number of vasculogenic vessels relative to angiogenic vessels, lacZ-positive vessels comprised Ͻ5% in control B16F10 tumors, consistent with published reports (60 -62) . Interestingly, we have found that donor BM-derived vessels were not located uniformly through the tumor but occurred in clusters around the tumor periphery, suggesting that local cues, in addition to VEGF/PlGF overexpression, modulate this process. Ex vivo expanded EPCs (CE-EPCs) were used to further study the role of VEGF and VEGFRs in postnatal vasculogenesis as used in other studies (4, 41, 63, 64) . VEGFR1 immunoneutralization resulted in consistent, statistically significant reduction in homing of exogenously administered EPCs, whereas VEGFR2 blockade had variable effects. VEGFR1 transcript expression was modestly higher in cultured EPCs than in ECs whereas VEGFR2 transcripts were much higher in ECs. The relatively lower VEGFR2 expression on CEEPCs may explain the greater role played by VEGFR1 in CE-EPC migration in vitro and may be a partial explanation for the variable inhibition of homing observed with the VEGFR2-blocking antibodies. Consistent with the predominant role of VEGFR1 in cultured EPC recruitment in vivo, the VEGFR1 agonist PlGF had a significantly more robust effect on EPC chemotaxis as compared with ECs. It is well established that VEGF is a potent monocyte chemoattractant, and this effect is mediated by VEGFR1 (22, 65, 66) . VEGF-induced EPC migration in vivo was mediated primarily by VEGFR1. The data suggest that VEGF-VEGFR1 interactions in EPCs are distinct from differentiated ECs and that receptor specificity for the migration response may be lineage dependent.
Recent work has implicated ischemia-associated SDF-1 expression as important for CE-EPC recruitment in murine wound models (14, 17) . Our data suggest that VEGF and SDF-1 likely act independently on EPCs to promote vasculogenesis.
In addition to EPC recruitment to the site of tumor vasculogenesis, our data also support a role for VEGF in the formation of functional vessels by exogenous CEEPCs. Pretreatment of CE-EPCs with blocking antibodies to either VEGFR blocked assembly into functional vessels. In addition, blocking VEGFR2, but not VEGFR1, resulted in reduced viability of CE-EPCs. This suggests that VEGF/VEGFR2 signaling may provide necessary survival cues. These studies do not exclude the possibility that VEGF also has direct effects on the vascular endothelium to up-regulate adhesion molecules that promote leukostasis or its potential effects to increase vessel permeability and resultant extravasation of serum proteins leading to enhanced blood vessel formation (21, 67) . Studies are underway to more completely define VEGF's role in postnatal vasculogenesis to determine how modulating VEGF signaling may affect this process during tumor and ischemic neovascularization.
from a GUSB-deficient mouse. Both polymerase chain reaction and histochemical stain for GUSB demonstrated absence of GUSB enzyme activity. Each transplanted recipient received subcutaneous implantation of 2 ϫ 10 6 GUSB Ϫ/Ϫ tumor cells with and without admixed VEGF in opposing flanks. By both immunofluorescent and histochemical analysis, GUSB-positive cells were detected in tumor sections that resembled vascular structures and colocalized with BS1 lectinpositive cells. We used flow cytometric analysis of collagenase-treated tumor suspensions to quantify the numbers of GUSB-positive (BM-derived) cells that coexpressed VE-cadherin, a marker specific for ECs. VEGF-containing tumors isolated after 5 days of implantation contained a significantly greater percentage of BM-derived ECs (GUSB/VE-cadherin dual positive), 30.8 Ϯ 8.2 vs. 10 Ϯ 4.8%, P Ͻ 0.05. This effect of VEGF was not statistically different from control in tumors obtained 25 days after implantation. The lack of effect of VEGF at day 25 was likely due to the short bioavailability of rVEGF. The analysis of tumor homogenates after 5 days of implantation supported our findings from the flk1/lacZ/BMT-melanoma tumor model that tumor-associated-increased VEGF levels promoted increased vasculogenesis at the site of tumor growth.
VEGFR1 mediates EPC recruitment to site of tumorigenesis
The role of VEGFRs in EPC recruitment in vivo was investigated by preincubation of human EPCs with receptor-specific antibodies that blocked both ligand binding and activation. GUSB Ϫ/Ϫ mice were inoculated subcutaneously with 1 ϫ 10 6 GUSB Ϫ/Ϫ sarcoma cells. After 10 days of tumor growth (tumor vol. Ϸ0.5 cm 3 ), mice were injected intravenously with 5 ϫ 10 5 human peripheral blood-derived CE-EPCs preincubated with either anti-VEGFR1-or -VEGFR2-blocking antibodies or control IgG. The mice were killed 12 h after administration, and their tumors were homogenized and assayed for GUSB enzyme activity as a quantitative marker for administered CE-EPCs. GUSB specific activity (1 Uϭnmol/mg protein/h) in lung (as an example of normal tissue) was very low and similar between treated and control animals, 140 Ϯ 20 vs. 110 Ϯ 29 U, respectively. By contrast, GUSB specific activity in tumor tissue was Ϸ10-fold (1320Ϯ80 U) higher than that in the lung of control animals. Preincubation with VEGFR1 antibody resulted in fivefold decrease in total GUSB activity in tumors as compared with tumors from mice receiving CE-EPCs preincubated with control IgG. Preincu- bation of EPCs with anti-VEGFR2 antibody diminished CE-EPC recruitment, but this was not statistically significant. Tumors from mice receiving PBS injections served as negative control and demonstrated no GUSB activity.
VEGFR-blocking antibodies prevent CE-EPC mediated vessel formation in tumors
To distinguish CE-EPC survival and vessel formation from recruitment effects of receptor-blocking antibodies, we preincubated 5 ϫ 10 5 CE-EPCs in the presence of anti-VEGFR2 or -VEGFR1 antibodies or IgG control before subcutaneous administration with 2 ϫ 10 6 tumor cells. Each mouse was implanted with all three conditions, thereby generating three foci of solid tumors. Tumors were removed after 8 days for analysis of functional vessel formation by GUSB-positive CE-EPCs. Control tumors contained numerous GUSB-positive cells, many that had assembled into vascular-like structures. CE-EPC-derived functional vessels were identified by colocalizing CE-EPC-derived vessels using humanspecific anti-von Willebrand factor (vWF) antibody with BS1-lectin positive structures, which marked functional tumor vessels. Abundant GUSB-positive cells were also evident in tumors in which CE-EPCs preincubated with VEGFR1 antibodies had been added; however, no donor-derived, vWF-positive vessels in tumors were found. Although clusters of cells were evident, no cord-like structures were evident in experiments in which cells were preincubated with anti-VEGFR1 or VEGFR2. There were far fewer intact GUSB-positive cells derived from CE-EPCs preincubated with anti-VEGFR2 than control IgG. Unlike VEGFR1-blocking antibodies, the presence of VEGFR2-blocking antibodies significantly diminished (Ϸ3-fold) the numbers of intact CE-EPCs in tumors as determined by counting intact numbers of GUSB-positive cells in representative fields from three different tumors. Thus, either VEGFR1-or VEGFR2-blocking antibodies prevented CE-EPC assembly into vesselswithin the tumor mass; VEGFR2 inhibition diminished CE-EPC viability.
VEGF/VEGFR1 interactions play a unique role in VEGF-mediated CE-EPC migration in vitro
By using a modified Boyden chamber migration assay, we showed that CE-EPCs migrated in a dose-dependent manner to both VEGF and the VEGFR1-specific agonist PlGF. To examine receptor specificity, CE-EPCs were preincubated in receptor-blocking anti-VEGFR1 or -VEGFR2 for 60 min before migration assay. Migration of CE-EPCs was equally responsive to PlGF, a VEGFR1-specific agonist, as VEGF. Concentration of inhibition by VEGFR1-blocking antibody was commensurate with blocking anti-VEGFR2. By contrast, in vitro migration in response to VEGF of differentiated ECs was mediated primarily by VEGFR2, consistent with published studies. Hence, unlike ECs, CE-EPC migration in vitro was mediated by both receptors.
CONCLUSIONS AND SIGNIFICANCE
Published data have shown that VEGF enhances EPC mobilization and survival in circulation (Fig. 2) . In this study, we showed that VEGF promotes tumor vasculogenesis by mechanisms that include events downstream of these effects (Fig. 2) . We also found that tumorexpressed PlGF, a VEGFR1-specific agonist, also promotes tumor vasculogenesis (Fig. 2) . Consistent with this, we found that VEGF/VEGFR1 interactions modulate CE-EPC recruitment to tumors. Pretreatment of CE-EPCs with blocking antibodies to either VEGFRs blocked assembly into functional vessels. In addition, blocking VEGFR2, but not VEGFR1, resulted in reduced viability of CE-EPCs resident in tumors. This suggests that VEGF/VEGFR2 signaling may provide necessary survival cues. These data also support the hypothesis that the local microenvironment (i.e., local VEGF and/or PlGF levels) plays an important role in vasculogenesis. In this study, we show that enhanced tumor-associated VEGF and PlGF can enhance vasculogenesis. VEGFRs modulate EPC recruitment and vessel formation at tumor site.
